SNMMI continues advocacy on utility of amyloid imaging

03/27/2013 | MolecularImaging.net

SNMMI and the Alzheimer's Association will meet with CMS officials next month to discuss appropriate use criteria concerning the use of amyloid imaging in evaluating and diagnosing Alzheimer's disease. SNMMI President Frederic H. Fahey said SNMMI "will recommend coverage for the three indications specified by the AUC." Amyloid imaging is not currently reimbursed.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX